A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

Files in this item

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics